NRSN
NeuroSense Therapeutics Ltd.
Biotechnology
Market Cap$20M
5Y Perf.-64.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NRSN vs SAVA
Revenue, margins, valuation, and 5-year total return — side by side.
SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$94M
5Y Perf.-63.5%
NRSN vs SAVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NRSN | SAVA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $20M | $94M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-9M | $-106M |
| Total Debt | $73K | $0.00 |
| Cash & Equiv. | $3M | $129M |
NRSN vs SAVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NRSN
SAVA
| Stock | Dec 21 | May 26 | Return |
|---|---|---|---|
| NeuroSense Therapeu… (NRSN) | 100 | 35.7 | -64.3% |
| Cassava Sciences, I… (SAVA) | 100 | 36.5 | -63.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NRSN vs SAVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SAVA leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. NeuroSense Therapeutics Ltd. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
NRSN
NeuroSense Therapeutics Ltd.
The Income Pick
NRSN is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.27
- Lower volatility, beta 1.27, Low D/E 2.8%, current ratio 2.21x
- Beta 1.27, current ratio 2.21x
Best for: income & stability and sleep-well-at-night
SAVA
Cassava Sciences, Inc.
The Growth Play
SAVA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 77.6%
- -19.5% 10Y total return vs NRSN's -78.3%
- 5.4% margin vs NRSN's -6.8%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRSN | -2.8% revenue growth vs SAVA's -5.4% |
| Quality / Margins | SAVA | 5.4% margin vs NRSN's -6.8% |
| Stability / Safety | NRSN | Beta 1.27 vs SAVA's 2.02 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SAVA | +25.3% vs NRSN's -14.0% |
| Efficiency (ROA) | SAVA | -75.3% ROA vs NRSN's -5.1% |
NRSN vs SAVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSAVALAGGINGNRSN
NRSNNeuroSense Therapeuti…
0leads
SAVACassava Sciences, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs NRSNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SAVA1/1
Valuation MetricsMultiples, price ratios, and targets
SAVA2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SAVA5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
SAVA5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SAVA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NRSN and SAVA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$9M | -$110M |
| Net IncomeAfter-tax profit | -$9M | -$106M |
| Free Cash FlowCash after capex | -$2,000 | -$84M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -95.2% | +62.1% |
SAVA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
SAVA leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… |
|---|---|---|
| Market CapShares × price | $20M | $94M |
| Enterprise ValueMkt cap + debt − cash | $17M | -$34M |
| Trailing P/EPrice ÷ TTM EPS | -1.59x | -3.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 6.32x | 0.63x |
| Price / FCFMarket cap ÷ FCF | — | — |
SAVA leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
SAVA leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
SAVA delivers a -95.8% return on equity — every $100 of shareholder capital generates $-96 in annual profit, vs $-29 for NRSN. On the Piotroski fundamental quality scale (0–9), NRSN scores 3/9 vs SAVA's 2/9, reflecting mixed financial health.
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… |
|---|---|---|
| ROE (TTM)Return on equity | -28.8% | -95.8% |
| ROA (TTM)Return on assets | -5.1% | -75.3% |
| ROICReturn on invested capital | — | -6.3% |
| ROCEReturn on capital employed | -8.6% | -99.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.03x | — |
| Net DebtTotal debt minus cash | -$3M | -$129M |
| Cash & Equiv.Liquid assets | $3M | $129M |
| Total DebtShort + long-term debt | $73,000 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -97.39x | — |
SAVA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
SAVA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SAVA five years ago would be worth $3,302 today (with dividends reinvested), compared to $2,171 for NRSN. Over the past 12 months, SAVA leads with a +25.3% total return vs NRSN's -14.0%. The 3-year compound annual growth rate (CAGR) favors SAVA at -16.0% vs NRSN's -20.3% — a key indicator of consistent wealth creation.
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… |
|---|---|---|
| YTD ReturnYear-to-date | +12.4% | -6.5% |
| 1-Year ReturnPast 12 months | -14.0% | +25.3% |
| 3-Year ReturnCumulative with dividends | -49.3% | -40.8% |
| 5-Year ReturnCumulative with dividends | -78.3% | -67.0% |
| 10-Year ReturnCumulative with dividends | -78.3% | -19.5% |
| CAGR (3Y)Annualised 3-year return | -20.3% | -16.0% |
SAVA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NRSN and SAVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
NRSN is the less volatile stock with a 1.27 beta — it tends to amplify market swings less than SAVA's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SAVA currently trades 39.3% from its 52-week high vs NRSN's 33.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 2.02x |
| 52-Week HighHighest price in past year | $2.60 | $4.98 |
| 52-Week LowLowest price in past year | $0.63 | $1.51 |
| % of 52W HighCurrent price vs 52-week peak | +33.7% | +39.3% |
| RSI (14)Momentum oscillator 0–100 | 63.3 | 46.8 |
| Avg Volume (50D)Average daily shares traded | 157K | 712K |
Evenly matched — NRSN and SAVA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SAVA leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallCassava Sciences, Inc. (SAVA)Leads 4 of 6 categories
Loading custom metrics...
NRSN vs SAVA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NRSN or SAVA a better buy right now?
Analysts rate Cassava Sciences, Inc.
(SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NRSN or SAVA?
Over the past 5 years, Cassava Sciences, Inc.
(SAVA) delivered a total return of -67. 0%, compared to -78. 3% for NeuroSense Therapeutics Ltd. (NRSN). Over 10 years, the gap is even starker: SAVA returned -19. 5% versus NRSN's -78. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NRSN or SAVA?
By beta (market sensitivity over 5 years), NeuroSense Therapeutics Ltd.
(NRSN) is the lower-risk stock at 1. 27β versus Cassava Sciences, Inc. 's 2. 02β — meaning SAVA is approximately 59% more volatile than NRSN relative to the S&P 500.
04Which is growing faster — NRSN or SAVA?
On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.
grew EPS 77. 6% year-over-year, compared to 33. 7% for NeuroSense Therapeutics Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NRSN or SAVA?
NeuroSense Therapeutics Ltd.
(NRSN) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Cassava Sciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NRSN leads at 0. 0% versus 0. 0% for SAVA. At the gross margin level — before operating expenses — NRSN leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NRSN or SAVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NRSN or SAVA better for a retirement portfolio?
For long-horizon retirement investors, NeuroSense Therapeutics Ltd.
(NRSN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 27)). Cassava Sciences, Inc. (SAVA) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NRSN: -78. 3%, SAVA: -19. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NRSN and SAVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.